This year's American Society of Clinical Oncology program includes promising data from Novartis AG's pilot study of the company's next-generation CAR-T therapy CTL119 with Johnson & Johnson/AbbVie Inc.'s BTK blockbuster Imbruvica, along with a number of interesting discussions and lectures about where the field is going.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?